Polatuzumab Vedotin | Anti-CD79b | Therapeutic ADC

Aliquoted from the original drug | Now available for research use

Aliquots of the reference drug Polatuzumab Vedotin are now available as research consumables.

Polatuzumab Vedotin drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.

Not looking for Polatuzumab Vedotin Reference drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Polivy® / Polatuzumab Vedotin Reference Product

Drug namePolivy®
INNPolatuzumab Vedotin
API typeADC
Pharmacotherapeutic group
Antineoplastic agents; other antineoplastic agents
ATC code
L01FX14
Target of antibody
CD79b
General function
Short descriptionPolatuzumab Vedotin is an antibody-drug conjugate composed of the anti-mitotic agent monomethyl
auristatin E (MMAE) covalently conjugated to a CD79b-directed monoclonal antibody (recombinant
humanized immunoglobulin G1 [IgG1].
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Polatuzumab Vedotin is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E, or MMAE) to B-cells, which results in the killing of malignant B-cells. The Polatuzumab Vedotin molecule consists of MMAE covalently attached to a humanized immunoglobulin G1 monoclonal antibody via a cleavable linker. The monoclonal antibody binds with high affinity and selectivity to CD79b, a cell surface component of the B-cell receptor.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Polatuzumab Vedotin did not prolong the mean QTc interval to any clinically relevant extent based on ECG data from two open-label studies in patients with previously treated B-cell malignancies at the recommended dosage.
Original license holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Marketing authorisation numbers
EU/1/19/1388/002
Marketing authorisation holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Name of the manufacturer of the biological active substance
Lonza Ltd.
Lonzastrasse
CH-3930 Visp
Switzerland
Name and address of the manufacturer(s) responsible for batch releaseRoche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
Max shelf life
30 months
Storage conditions
2°C – 8°C
List of excipients
Succinic acid
Sodium hydroxide (for pH-adjustment)
Sucrose
Polysorbate 20 (E 432)

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting